Time for another round-up of some of the great articles my colleagues here at About.com have written. I have hand-picked each article so as to offer information that I think may be of use to all of you in terms of your overall digestive health. There are quite of few of them, so you may want to bookmark this page as a reference as you won't want to miss any of them. Enjoy!

...

Read Full Post

Intestinal worms were once a common menace to all classes
Bloomington Pantagraph
“She was restless in her sleep, suffered with indigestion, heartburn, dizziness and constipation,” read a Shorthose advertisement for Dunn's patent medicine line. “Authorities pronounced it a case of incurable chronic stomach troubles, and it really ...

Sucampo Pharmaceuticals Inc. surged 42 percent over two days after reporting that its experimental medicine for opioid-induced bowel dysfunction met goals in a late-stage clinical trial.

Quite a while ago I discussed an interesting theoretical article about a relationship between the appendix and IBS symptoms: "IBS and the Appendix: A Unique Theory". Many years later, a person who claims to be the author of that article found my blog and left an thought-provoking comment:

...

Read Full Post

PR Web (press release)
Press release from The Pulse Light Clinic "Positive results using IPL and diet ...
PR Web (press release)
Constipated 58% had slow moving bowels which results in auto-intoxication, weight gain (more calories are absorbed form the stool while it sits in the colon) and subsequent free radical damage. Food Intolerance (involving IgG antibodies) 80% had more ...

Phase 3 study of lubiprostone for treatment of opioid-induced bowel ...
pharmabiz.com
There are more than 200 million prescriptions for opioid use in the US annually and a substantial portion of these prescriptions are for non-cancer chronic pain. Many patients are not getting the desired relief and there is a significant need for a new ...

Acorda Therapeutics Presents Preclinical Data Showing Dalfampridine Improves ...
EON: Enhanced Online News (press release)
“These are the first preclinical data to show an oral pharmacologic treatment can improve function in chronic, or long term, stroke. We are excited by these results and plan to begin proof-of-concept human clinical trials of AMPYRA in people with ...

and more »

Sucampo Pharmaceuticals Inc. surged for a second day after reporting that its experimental medicine for opioid-induced bowel dysfunction met goals in a late-stage clinical trial.

Amazing Health Benefits Of Eggs
Manila Bulletin
... or throat; tingling in the mouth; wheezing or nasal congestion; trouble breathing; and dizziness or lightheadedness and can also include fatigue, depression, chronic headache, chronic bowel problems (such as diarrhea or constipation), and insomnia.

Acorda Therapeutics Inc. Posted on:03 Feb 12 Acorda Therapeutics, Inc. (Nasdaq: ACOR ) presented data showing that treatment with dalfampridine improved motor function in a preclinical model of stroke, with treatment initiated at least four weeks following the ischemic event.

Acorda Therapeutics Presents Preclinical Data Showing Dalfampridine Improves ...
MarketWatch (press release)
"These are the first preclinical data to show an oral pharmacologic treatment can improve function in chronic, or long term, stroke. We are excited by these results and plan to begin proof-of-concept human clinical trials of AMPYRA in people with ...

and more »

Acorda Therapeutics, Inc. presented data showing that treatment with dalfampridine improved motor function in a preclinical model of stroke, with treatment initiated at least four weeks following the ischemic event.

After a successful phase 3 clinical trial, Sucampo Pharmaceuticals of Bethesda is ready to apply for U.S. regulatory approval to market its constipation drug to people who have bowel dysfunction from taking morphine and codeine for chronic, non-cancer pain.

RTT News
Constipation drug offers more potential for Bethesda's Sucampo
Gazette.Net: Maryland Community News Online
Lubiprostone already is marketed under the name Amitiza to treat chronic idiopathic constipation and irritable bowel syndrome with constipation. Approval of lubiprostone for this third condition would be a shot in the arm for Sucampo, which said in its ...
Lubiprostone Meets Primary Endpoint in Phase 3 Clinical Trial for Opioid ...MarketWatch (press release)
Sucampo Pharma's Lubiprostone Meets Key Goal In Phase III Trial For OBD - UpdateRTT News
Sucampo Gains as Bowel Drug Shows Effectiveness in Study: Washington MoverBloomberg
BusinessWeek
all 26 news articles »

I have finally tackled a long overdue series on digestive enzymes. I know that many of you have heard the term bandied about as possibly being helpful for IBS. My first article in the series, offers you basic (okay, maybe a little boring) information about what these enzymes are and why they are important for the process of digestion:

...

Read Full Post

Thyroid function important during pregnancy
Waterloo Record
Some women may already have a thyroid disorder when they become pregnant, but had stopped taking medication because they didn't realize it's a chronic condition. “You're dealing with a common condition and it's more common in women, so looking for it ...

and more »

(Photos: Pacific Coast News, Getty Images, Flynet Picutres) Simply by being in the public eye, celebrities open themselves up to constant speculation and hearsay, and somehow the most absurd rumors take on a life of their own and become full-blown conspiracy theories. These urban legends are too far-out even for tabloids and their "sources" to report with any semblance of credibility, but enough ...

Sucampo Pharmaceuticals Inc. (SCMP) and Takeda Pharmaceuticals U.S.A., Inc. announced Thursday that their drug lubiprostone, marketed under the trade name Amitiza, met the primary endpoint in a late-stage clinical trial for opioid-induced bowel dysfunction, or OBD.

Sucampo Pharmaceuticals Inc. (SCMP) and Takeda Pharmaceuticals U.S.A., Inc. announced Thursday that their drug lubiprostone, marketed under the trade name Amitiza, met the primary endpoint in a late-stage clinical trial for opioid-induced bowel dysfunction, or OBD.

Sucampo Pharmaceuticals Inc. Posted on:02 Feb 12 Sucampo Pharmaceuticals, Inc. (NASDAQ: SCMP) (SPI) and Takeda Pharmaceuticals U.S.A., Inc. announced today that lubiprostone met the primary endpoint in a phase 3 clinical trial for the treatment of opioid-induced bowel dysfunction (OBD) in patients with chronic, non-cancer pain, excluding those taking methadone.